Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 5:11:496.
doi: 10.3389/fneur.2020.00496. eCollection 2020.

Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias

R Scott Turner  1 , Terry Stubbs  2 , Don A Davies  3 , Benedict C Albensi  3   4
Affiliations
Review

Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias

R Scott Turner et al. Front Neurol. .

Abstract

Dementia is an umbrella term-caused by a large number of specific diagnoses, including several neurodegenerative disorders. Alzheimer's disease (AD) is now the most common cause of dementia in advanced countries, while dementia due to neurosyphilis was the leading cause a century ago. Many challenges remain for diagnosing dementia definitively. Some of these include variability of early symptoms and overlap with similar disorders, as well as the possibility of combined, or mixed, etiologies in some cases. Newer technologies, including the incorporation of PET neuroimaging and other biomarkers (genomics and proteomics), are being incorporated into revised diagnostic criteria. However, the application of novel diagnostic methods at clinical sites is plagued by many caveats including availability and access. This review surveys new diagnostic methods as well as remaining challenges-for clinical care and clinical research.

Keywords: Alzheimer; clinic; dementia; diagnostic; memory; novel.

PubMed Disclaimer

References

    1. Pietrzak K, Czarnecka K, Mikiciuk-Olasik E, Szymanski P. New perspectives of alzheimer disease diagnosis—the most popular and future methods. Med Chem. (2018) 14:34–43. 10.2174/1573406413666171002120847 - DOI - PubMed
    1. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. . Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. (2018) 14:639–52. 10.1038/s41582-018-0079-7 - DOI - PMC - PubMed
    1. Chertkow H, Black S. Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci. (2007) 34(Suppl. 1):S77–83. 10.1017/s031716710000562x - DOI - PubMed
    1. Blennow K, Zetterberg H. Use of CSF biomarkers in Alzheimer's disease clinical trials. J Nutr Health Aging. (2009) 13:358–61. 10.1007/s12603-009-0043-8 - DOI - PubMed
    1. Kerr NL. HARKing: hypothesizing after the results are known. Pers Soc Psychol Rev. (1998) 2:196–217. 10.1207/s15327957pspr0203_4 - DOI - PubMed

LinkOut - more resources